AU2023250653A1 - Compositions and methods for treating polymyalgia rheumatica by administering an il‑6r antagonist - Google Patents

Compositions and methods for treating polymyalgia rheumatica by administering an il‑6r antagonist Download PDF

Info

Publication number
AU2023250653A1
AU2023250653A1 AU2023250653A AU2023250653A AU2023250653A1 AU 2023250653 A1 AU2023250653 A1 AU 2023250653A1 AU 2023250653 A AU2023250653 A AU 2023250653A AU 2023250653 A AU2023250653 A AU 2023250653A AU 2023250653 A1 AU2023250653 A1 AU 2023250653A1
Authority
AU
Australia
Prior art keywords
antibody
antigen
binding fragment
week
pmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023250653A
Other languages
English (en)
Inventor
Bolanle Akinlade
Lita ARAUJO
Jeffrey Curtis
Stefano FIORE
Kerri FORD
Angeliki GIANNELOU
Danielle ISAMAN
Yong Lin
Ying Liu
Frédéric MARRACHE
Chad NIVENS
Jennifer SLOANE LAZAR
Wanling WONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of AU2023250653A1 publication Critical patent/AU2023250653A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023250653A 2022-04-06 2023-04-05 Compositions and methods for treating polymyalgia rheumatica by administering an il‑6r antagonist Pending AU2023250653A1 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202263327850P 2022-04-06 2022-04-06
US63/327,850 2022-04-06
US202263350761P 2022-06-09 2022-06-09
US63/350,761 2022-06-09
US202263389317P 2022-07-14 2022-07-14
US63/389,317 2022-07-14
US202263424035P 2022-11-09 2022-11-09
US63/424,035 2022-11-09
US202263424627P 2022-11-11 2022-11-11
US63/424,627 2022-11-11
US202363445331P 2023-02-14 2023-02-14
US202363445329P 2023-02-14 2023-02-14
US63/445,331 2023-02-14
US63/445,329 2023-02-14
US202363447796P 2023-02-23 2023-02-23
US63/447,796 2023-02-23
PCT/US2023/065361 WO2023196838A1 (en) 2022-04-06 2023-04-05 Compositions and methods for treating polymyalgia rheumatica by administering an il‑6r antagonist

Publications (1)

Publication Number Publication Date
AU2023250653A1 true AU2023250653A1 (en) 2024-11-21

Family

ID=86424726

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023250653A Pending AU2023250653A1 (en) 2022-04-06 2023-04-05 Compositions and methods for treating polymyalgia rheumatica by administering an il‑6r antagonist

Country Status (11)

Country Link
US (1) US20230399410A1 (https=)
EP (1) EP4504788A1 (https=)
JP (2) JP7630012B2 (https=)
KR (1) KR20240164816A (https=)
CN (1) CN120569404A (https=)
AU (1) AU2023250653A1 (https=)
CA (1) CA3247400A1 (https=)
IL (1) IL316091A (https=)
MX (1) MX2024012345A (https=)
TW (1) TW202405014A (https=)
WO (1) WO2023196838A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025149845A1 (en) * 2024-01-12 2025-07-17 Sanofi Biotechnology Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid
WO2025149846A1 (en) * 2024-01-12 2025-07-17 Sanofi Biotechnology Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2017106312A1 (en) * 2015-12-18 2017-06-22 Drexel University Methods of modulating levels of il-6 and pd-l1
EP3980459A1 (en) * 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Also Published As

Publication number Publication date
MX2024012345A (es) 2024-11-08
IL316091A (en) 2024-12-01
JP2025072440A (ja) 2025-05-09
TW202405014A (zh) 2024-02-01
US20230399410A1 (en) 2023-12-14
WO2023196838A1 (en) 2023-10-12
KR20240164816A (ko) 2024-11-20
EP4504788A1 (en) 2025-02-12
JP2024526414A (ja) 2024-07-18
CA3247400A1 (en) 2023-10-12
JP7630012B2 (ja) 2025-02-14
CN120569404A (zh) 2025-08-29

Similar Documents

Publication Publication Date Title
US20260027202A1 (en) Treatment of rheumatoid arthritis with an il-6r antibody
US9943594B2 (en) Methods for the treatment of rheumatoid arthritis
EP3071230B1 (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
JP2025072440A (ja) Ｉｌ－６ｒアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法
US20230127528A1 (en) Compositions and methods for treating juvenile idiopathic arthritis
TW201808993A (zh) 用於治療類風濕性關節炎之組成物及方法
US20250388685A1 (en) Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
RU2822089C2 (ru) Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита
WO2025149845A1 (en) Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid
WO2025149846A1 (en) Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist
IL265949A (en) Preparations for the treatment of rheumatoid arthritis and methods of using them
HK1195495B (en) Compositions for the treatment of rheumatoid arthritis and methods of using the same
HK1195495A (en) Compositions for the treatment of rheumatoid arthritis and methods of using the same
HK1225635B (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
HK1225635A1 (en) Compositions for the treatment of rheumatoid arthritis and methods of using same

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF A CO-INVENTOR TO READ AKINLADE, BOLANLE